Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02955849
Other study ID # SLT in rural China
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date September 2016
Est. completion date December 2019

Study information

Verified date November 2016
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Aims and Objectives (Quantitative) Aim: To compare the effectiveness of selective laser trabeculoplasty with trabeculoplasty in lowering the intraocular pressure in patients with medically uncontrolled open angle glaucoma in rural China, taking into account the impact of patient acceptance of each type of treatment Hypothesis: Mean intraocular pressure after treatment with selective laser trabeculoplasty will be lower than with surgery due to higher acceptance rates among patients randomized to receive this treatment and therefore treatment provided at an earlier stage of disease progression.


Description:

Glaucoma is one of the three leading causes of blindness in China. Although this condition can be controlled with medication to lower intraocular pressure , such treatment must continue over a patient's lifetime. This is not practical in resource-poor settings due to cost and inconvenience for patients. Trabeculectomy is the standard treatment offered in rural China but is rarely used because of the following issues: 1. need for hospitalization, which increases patient expense and inconvenience 2. high refusal rates by patients for all ocular surgery 3. high rates of infection due to poor quality instruments and material 4. need for multiple follow-up visits post-surgery (our earlier work shows a return rate of only 30% 1 month post-surgery among rural patients in China). A viable alternative for patients in rural China is selective laser trabeculoplasty , based on the following advantages: 1. simplicity (done as a 5-minute out-patient procedure requiring only topical anaesthesia) 2. effectiveness (18-32% reduction in intraocular pressure, which is comparable to medication) 3. safety (complications are rare and do not include serious infectious as with trabeculotemy) 4. convenience (minimal follow-up, with one visit within 6 weeks post-surgery) 5. cost-effectiveness (compared to other glaucoma therapies in many settings) 6. acceptability to patients (due to low-cost out-patient care with easy follow-up). Study Design (Quantitative) This phase of the proposed China Laser and Surgery Study research project is a multi-centre open-label pragmatic randomised controlled trial. Expected timeline: - Enrolment: 12 months - Follow-up: 12 months - Data analysis: 4 months Patient Population and Setting: Patients presenting with glaucoma at rural hospitals (n=4) in Guangdong province, China, all of whom are currently capable of performing trabeculectomy surgery, and have been provided an selective laser trabeculoplasty machine and training in its use. Sample Size: One hundred ninety patients (95 in each group) will be needed to obtain a power of 0.90, with a two-sided alpha of 0.05. Patients are the unit of randomization. Expected IOP difference between groups of 3.0 mm Hg + 4.0 mmg HG, and a correlation of 0.30 between baseline and final intraocular pressure, allowing for loss to follow up of 30%. Baseline Data: aseline data (to be collected prior to determination of eligibility and randomization but after obtaining informed consent) include the following: - Presence or absence of relevant pre-existing health conditions (i.e., hypertension, diabetes, cardiovascular disease) - Ophthamologic test results - Best corrected visual acuity and presenting visual acuity in both eyes - Intraocular pressure in both eyes - Cup to disk ratio in both eyes - presence or absence of visually significant cataract in both eyes; if cataract present in study eye, whether cataract surgery has already been performed - degrees of visible Trabecular Meshwork in the study eye on gonioscopy without "dynamic gonioscopy" - score on glaucoma knowledge test using a simple, previously validated questionnaire - Demographic data - date of birth or self-reported age in years - sex - Contact information - Address - mobile phone number where can be reached (own or neighbours, etc.) - Socioeconomic status - completed education in years - wealth, as measured by ownership of items on a pre-determined list of 13 common household devices in China - job title/description - Level of difficulty traveling to hospital with eye clinic - distance traveled - time spent traveling - direct or out-of-pocket costs for travel, meals, etc. Main analyses: - Following requirements for intention-to-treat analyses, we will measure mean intraocular pressure at 12 months comparing the two groups and adjusting for baseline intraocular pressure, including all subjects who accepted and refused treatment (primary analysis, unadjusted). We will also measure intraocular pressure as above, adjusting for cataract surgery, age, gender, prior use of medication, degrees of open angle in study eye at baseline, and severity of glaucoma (Cup to disk ratio) in study eye at baseline (primary analysis, adjusted). Both of the above analyses will be repeated using a per protocol approach (including only patients who accepted their assigned therapy, or secondary analysis). - We will test for differences in baseline characteristics by study group with t-tests (for continuous variables) and Chi-square tests (for categorical variables). We will use generalized linear models with Poisson regression (for variables with binary outcomes) and linear regression (for variables with continuous outcomes) to estimate the relative risk for the intervention arm. Multiple imputation in Stata 13.1 (StataCorp, College Station, TX, USA) will be used to address missing data. All statistical analysis will be performed using Stata 13.1. A two-tailed P-value of <0.05 will be considered statistically significant.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date December 2019
Est. primary completion date December 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - diagnosis of glaucoma (Cup to disk ratio, or CDR > 0.6 with optic nerve appearance and/or visual field findings consistent with glaucoma in the study eye) - angle configuration > 180° of trabecular meshwork visible in the study eye - no previous ocular incisional surgery or ocular laser treatment except refractive or cataract surgery in the study eye - Best corrected visual acuity > 6/60 metres in both eyes Exclusion Criteria: - Intraocular pressure > 35 in the study eye - Cup to disk ratio > 0.9 in the study eye - Inability to give informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
SLT laser
Patients will be offered initial SLT laser by doctors

Locations

Country Name City State
China Blindness Preventment and Treatment Department Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

References & Publications (8)

Adekoya BJ, Akinsola FB, Balogun BG, Balogun MM, Ibidapo OO. Patient refusal of glaucoma surgery and associated factors in Lagos, Nigeria. Middle East Afr J Ophthalmol. 2013 Apr-Jun;20(2):168-73. doi: 10.4103/0974-9233.110612. — View Citation

Ang GS, Varga Z, Shaarawy T. Postoperative infection in penetrating versus non-penetrating glaucoma surgery. Br J Ophthalmol. 2010 Dec;94(12):1571-6. doi: 10.1136/bjo.2009.163923. Epub 2009 Nov 5. Review. — View Citation

Liang YB, Friedman DS, Wong TY, Zhan SY, Sun LP, Wang JJ, Duan XR, Yang XH, Wang FH, Zhou Q, Wang NL; Handan Eye Study Group. Prevalence and causes of low vision and blindness in a rural chinese adult population: the Handan Eye Study. Ophthalmology. 2008 Nov;115(11):1965-72. doi: 10.1016/j.ophtha.2008.05.030. Epub 2008 Aug 5. — View Citation

Liu T, Congdon N, Yan X, Jin L, Wu Y, Friedman D, He M. A randomized, controlled trial of an intervention promoting cataract surgery acceptance in rural China: the Guangzhou Uptake of Surgery Trial (GUSTO). Invest Ophthalmol Vis Sci. 2012 Aug 13;53(9):5271-8. doi: 10.1167/iovs.12-9798. — View Citation

Narayanaswamy A, Leung CK, Istiantoro DV, Perera SA, Ho CL, Nongpiur ME, Baskaran M, Htoon HM, Wong TT, Goh D, Su DH, Belkin M, Aung T. Efficacy of selective laser trabeculoplasty in primary angle-closure glaucoma: a randomized clinical trial. JAMA Ophthalmol. 2015 Feb;133(2):206-12. doi: 10.1001/jamaophthalmol.2014.4893. — View Citation

Realini T. Selective laser trabeculoplasty for the management of open-angle glaucoma in St. Lucia. JAMA Ophthalmol. 2013 Mar;131(3):321-7. doi: 10.1001/jamaophthalmol.2013.1706. — View Citation

Wittenborn JS, Rein DB. Cost-effectiveness of glaucoma interventions in Barbados and Ghana. Optom Vis Sci. 2011 Jan;88(1):155-63. doi: 10.1097/OPX.0b013e3181fc30f3. — View Citation

Zhang XJ, Liang YB, Liu YP, Jhanji V, Musch DC, Peng Y, Zheng CR, Zhang HX, Chen P, Tang X, Lam DS. Implementation of a free cataract surgery program in rural China: a community-based randomized interventional study. Ophthalmology. 2013 Feb;120(2):260-5. doi: 10.1016/j.ophtha.2012.07.087. Epub 2012 Oct 27. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Intraocular pressure intraocular pressure in study eye 12 months after receiving treatment (laser or surgery)
the intraocular pressure of patients refusing their allocated intervention will still be recorded at 12 months post-refusal and will be considered in the analysis
patients accepting the allocated treatment > 3 months after initial offer of treatment will be considered as having refused and their outcome intraocular pressure will be the last reading prior to treatment
12 months
Secondary Visual quality of life use the scale "NEI-VQ 25" to assess the patient's visual quality of life 12 months
Secondary Satisfaction score Using a Surgical Satisfaction Questionnaire previously validated in rural China 12 months
Secondary Cataract surgery Cataract surgery performed in conjunction with allocated treatment (Yes/No) 12 months
Secondary Allocated treatment use acceptance questionnaire form to calculate surgical receiving rate 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3